BioCentury
ARTICLE | Cover Story

It is an RNA world

July 24, 2014 7:00 AM UTC

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality.

The emergence of noncoding RNAs presents yet further opportunities for the modality, but a rudimentary understanding of the bioactivities of these molecules, the delivery hurdles and the difficulties of target selection and validation still surround this new therapeutic class...